Franklin Resources
NTLA icon

Franklin Resources’s Intellia Therapeutics NTLA Stock Holding History

Franklin Resources’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$175K Buy
+10,329
New +$145K ﹤0.01% 2881
2025
Q4 		– Sell
-10,239
Closed -$177K – 3222
2025
Q3 		$177K Buy
+10,239
New +$126K ﹤0.01% 2857
2025
Q2 		– Sell
-12,751
Closed -$90.7K – 3099
2025
Q1 		$90.7K Sell
12,751
-3,383
-21% -$34.2K ﹤0.01% 2819
2024
Q4 		$188K Sell
16,134
-271
-2% -$4.23K ﹤0.01% 2661
2024
Q3 		$320K Buy
16,405
+1,538
+10% +$35.5K ﹤0.01% 2464
2024
Q2 		$333K Sell
14,867
-2,377
-14% -$56.6K ﹤0.01% 2399
2024
Q1 		$474K Buy
17,244
+928
+6% +$25.8K ﹤0.01% 2275
2023
Q4 		$497K Buy
16,316
+2,372
+17% +$68.2K ﹤0.01% 1946
2023
Q3 		$441K Sell
13,944
-3,567
-20% -$138K ﹤0.01% 1983
2023
Q2 		$714K Buy
17,511
+7,642
+77% +$310K ﹤0.01% 1791
2023
Q1 		$368K Sell
9,869
-921
-9% -$36.1K ﹤0.01% 1795
2022
Q4 		$376K Buy
10,790
+298
+3% +$14.2K ﹤0.01% 1784
2022
Q3 		$588K Sell
10,492
-456,181
-98% -$28.3M ﹤0.01% 1647
2022
Q2 		$24.2M Sell
466,673
-499,965
-52% -$25.4M 0.01% 748
2022
Q1 		$70.2M Sell
966,638
-162,943
-14% -$13.8M 0.03% 511
2021
Q4 		$134M Buy
1,129,581
+150,131
+15% +$18.8M 0.05% 388
2021
Q3 		$131M Buy
979,450
+589,302
+151% +$89.2M 0.05% 389
2021
Q2 		$63.2M Buy
390,148
+376,767
+2,816% +$29.3M 0.02% 571
2021
Q1 		$1.07M Buy
13,381
+5,004
+60% +$336K ﹤0.01% 1466
2020
Q4 		$455K Buy
+8,377
New +$304K ﹤0.01% 1569
2017
Q2 		– Sell
-300,000
Closed -$4.23M – 1520
2017
Q1 		$4.23M Hold
300,000
– – ﹤0.01% 1131
2016
Q4 		$3.93M Hold
300,000
– – ﹤0.01% 1129
2016
Q3 		$5.11M Hold
300,000
– – ﹤0.01% 1101
2016
Q2 		$6.41M Buy
+300,000
New +$7.98M ﹤0.01% 1059

Other funds holding NTLA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Franklin Resources's NTLA Position: Q2 2026 in Review

Franklin Resources opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 10,329 shares worth $175K. The stake represents ﹤0.01% of the portfolio and ranks #2881 among its holdings. This is a return to the name: Franklin Resources previously reported a position in NTLA as recently as Q3 2025.

Franklin Resources first reported a position in NTLA in Q2 2016 and has held it in 24 quarters since. The position peaked at $134M in Q4 2021. 231 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Franklin Resources held 10,329 shares of Intellia Therapeutics worth $175K as of Q2 2026.
  • Intellia Therapeutics was a new Franklin Resources position in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Franklin Resources's portfolio in Q2 2026, its #2881 holding.
  • Franklin Resources first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 24 quarters since.
  • Franklin Resources's Intellia Therapeutics position peaked at $134M in Q4 2021.
  • 231 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.